Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy.

ABSTRACT: The care of systemic amyloidosis has improved dramatically due to improved awareness, accurate diagnostic tools, the development of powerful prognostic and companion biomarkers, and a continuous flow of innovative drugs, which translated into the blooming of phase 2/3 interventional studies for light chain (AL) and transthyretin (ATTR) amyloidosis. The unprecedented availability of effective drugs ignited great interest across various medical specialties, particularly among cardiologists who are now recognizing cardiac amyloidosis at an extraordinary pace. In all amyloidosis referral centers, we are observing a substantial increase in the prevalence of wild-type transthyretin (ATTRwt) cardiomyopathy, which is now becoming the most common form of cardiac amyloidosis. This review focuses on

SUBMITTER: Nuvolone M 

PROVIDER: S-EPMC9788438 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature